PathoGenetix Names Ann Merrifield as Chief Executive Officer and…

Experienced in developing high-growth biotechnology businesses, Merrifield will lead the commercialization of PathoGenetix’s proprietary Genome Sequence Scanning™ (GSS™) technology for application in...

(PRWeb December 05, 2012)

Read the full story at

Comments are closed.

Do NOT follow this link or you will be banned from the site!
%d bloggers like this: